Immunovant, Inc.
IMVT
Rank in Stocks
#3099
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Share Price
$28.44
Market Cap
$5.87B
Change (1 day)
-0.52%
Change (1 year)
47.89%
Country
US
Trade Immunovant, Inc. (IMVT)
Category
Healthcare
Stock price history for Immunovant, Inc. (IMVT)
Highest end of day price: $30.02 on 2026-10-01
Lowest end of day price: $9.88 on 2019-06-01
Lowest end of day price: $9.88 on 2019-06-01
Stock price history of Immunovant, Inc. from 2019 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 20.60% |
| 2025 | -7.38% |
| 2024 | -34.45% |
| 2023 | 163.89% |
| 2022 | 99.44% |
| 2021 | -84.02% |
| 2020 | 273.47% |
| 2019 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $520.80 | 22.18% |
US
|
|
| $249.05 | 805.97% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $885.14 | 6.04% |
NL
|
|
| $752.87 | 7.40% |
CH
|
